These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. [Switch therapy for community acquired pneumonia]. Aoshima M Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():326-30. PubMed ID: 17455640 [No Abstract] [Full Text] [Related]
47. New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: do not let the perfect be the enemy of the good. Corey GR; Stryjewski ME Clin Infect Dis; 2011 Jun; 52 Suppl 7():S469-76. PubMed ID: 21546623 [TBL] [Abstract][Full Text] [Related]
48. Shortening antibiotic duration for community acquired pneumonia. Melo L; Oliveira S Eur J Intern Med; 2018 May; 51():e21-e22. PubMed ID: 29454484 [No Abstract] [Full Text] [Related]
50. Early Clinical Response in Community-acquired Bacterial Pneumonia: From Clinical Endpoint to Clinical Practice. Ramirez JA; Tzanis E; Curran M; Noble R; Chitra S; Manley A; Kirsch C; McGovern PC Clin Infect Dis; 2019 Aug; 69(Suppl 1):S33-S39. PubMed ID: 31367741 [TBL] [Abstract][Full Text] [Related]
51. Solithromycin: A novel ketolide antibiotic. Buege MJ; Brown JE; Aitken SL Am J Health Syst Pharm; 2017 Jun; 74(12):875-887. PubMed ID: 28432048 [TBL] [Abstract][Full Text] [Related]
52. Community-acquired pneumonia: is it time to shorten the antibiotic treatment? Esposito S; Fiore M Expert Rev Anti Infect Ther; 2007 Dec; 5(6):933-8. PubMed ID: 18039078 [No Abstract] [Full Text] [Related]
53. Community acquired pneumonia. Loeb M Clin Evid; 2002 Jun; (7):1358-68. PubMed ID: 12230751 [No Abstract] [Full Text] [Related]
54. Drugs of choice for community-acquired bacterial pneumonia. Med Lett Drugs Ther; 2007 Jul; 49(1266):62-4. PubMed ID: 17652999 [No Abstract] [Full Text] [Related]
55. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL). Barrera CM; Mykietiuk A; Metev H; Nitu MF; Karimjee N; Doreski PA; Mitha I; Tanaseanu CM; Molina JM; Antonovsky Y; Van Rensburg DJ; Rowe BH; Flores-Figueroa J; Rewerska B; Clark K; Keedy K; Sheets A; Scott D; Horwith G; Das AF; Jamieson B; Fernandes P; Oldach D; Lancet Infect Dis; 2016 Apr; 16(4):421-30. PubMed ID: 26852726 [TBL] [Abstract][Full Text] [Related]
56. Monotherapy in severe community-acquired pneumonia: is it worthy? Torres A Chest; 2005 Jul; 128(1):10-3. PubMed ID: 16002907 [No Abstract] [Full Text] [Related]
57. Severe community acquired pneumonia. Mills GD; Laing R BMJ; 2006 Dec; 333(7580):1181-2. PubMed ID: 17158360 [TBL] [Abstract][Full Text] [Related]
58. Contemporary use of ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia: CAPTURE study experience. Ramani A; Udeani G; Evans J; Jandourek A; Cole P; Smith A; David Friedland H J Chemother; 2014 Aug; 26(4):229-34. PubMed ID: 24650326 [TBL] [Abstract][Full Text] [Related]